Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors

Materials & Design

Cheng Yi¹  Xi Yang²  Yuanfeng Wei²  Lingnan Zheng²  Jia You³  Huawei Li³  Jinfeng Liao⁴ 

[1] Corresponding authors at: Department of Medical Oncology, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, Sichuan, China (C. Yi).;Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China;Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, West Chengdu, China;State Key Laboratory of Oral Diseases, National Clinical Research Centre for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China;

关键词: Immune-related adverse events;    Nanoparticles;    Microneedles;    Cellular particulates;    Hydrogels;   

DOI  :  

来源: DOAJ

【 摘 要 】

Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of various types of cancer. However, even promising systemically administered ICB agents can cause immune-related adverse events (irAEs). The management of irAEs has been a significant concern. In addition to the risk of compromised immune function with corticosteroids and other immunomodulatory regimens used to treat irAEs, the complex mechanisms of irAEs make management of the “off-target” effects extremely challenging. Various materials with high biocompatibility, controllable degradability, and the ability for local and targeted delivery and controlled and sustained release of drugs have been explored to limit irAEs. Herein, we briefly review the fundamental mechanisms and clinical applications of immune checkpoint inhibitors and the potential mechanisms and clinical treatment of irAEs. We also highlight the application of emerging materials in the management of irAEs through “prevention” and “treatment”.

【 授权许可】

Unknown